secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-08-31T12:08:49+00:00
Accession:  0001193125-26-375495
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm submits sNDA for XPOVIO+ruxolitinib in myelofibrosis; seeks Priority Review
--------------------------------------------------------------------------------

- On Aug 31, 2026, submitted sNDA to FDA for XPOVIO (selinexor) plus ruxolitinib in myelofibrosis, requesting Priority Review.
- FDA decision on filing acceptance and review timelines expected in Q4 2026 after 60-day filing review period.
- Submission based on Phase 3 SENTRY trial data, including promising overall survival signal and positive benefit-risk profile.
- Accelerated Approval would require FDA to accept SVR35 (spleen volume reduction ≥35%) as surrogate endpoint for overall survival.
- Company plans to use long-term SENTRY overall survival data to verify clinical benefit and convert to traditional approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526375495/0001193125-26-375495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526375495/d423030d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-375495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer